OncoMatch/Clinical Trials/NCT04084717
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
Is NCT04084717 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Crizotinib for non-squamous non-small-cell lung cancer.
Treatment: Crizotinib — This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is at treating ROS1 or MET mutated non-small cell lung cancer. Crizotinib, also called XALKORI, is a chemotherapy drug that is currently approved for the treatment of ALK- or ROS1- positive advanced non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ROS1 rearrangement
documented ROS1 rearrangement (cohort 1)
Required: MET exon 14
MET-activating mutation (exon 14) (cohort 2)
Required: MET amplification
MET-amplification (cohort 3)
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: cytotoxic chemotherapy
Had chemotherapy (including investigational cytotoxic chemotherapy) within 4 weeks prior to the proposed first dose of study treatment
Cannot have received: biologic agent
biologic agents (e.g. targeted therapy or antibodies) within 4 weeks prior to the proposed first dose of study treatment
Cannot have received: radiation therapy
radiotherapy within 2 weeks prior to the proposed first dose of study treatment
Lab requirements
Blood counts
adequate hematologic function within 7 days of the proposed start date of treatment
Kidney function
adequate organ function within 7 days of the proposed start date of treatment
Liver function
adequate organ function within 7 days of the proposed start date of treatment
Cardiac function
adequate cardiac function within 28 days of the proposed start date of treatment
Adequate hematologic and organ function within 7 days of the proposed start date of treatment and adequate cardiac function within 28 days of the proposed start date of treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify